Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Aclaris Therapeutics. The associated price target remains the same with $16.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors related to Aclaris Therapeutics’ promising clinical data and strategic development plans. The recent Phase 2a trial results for ATI-2138, an investigational oral inhibitor, showed positive outcomes in patients with moderate-to-severe atopic dermatitis. The trial demonstrated that ATI-2138 has a favorable tolerability profile and can achieve clinically meaningful improvements in disease severity and itch reduction, even at low doses.
Furthermore, the trial results suggest that ATI-2138 may offer efficacy comparable to existing treatments with improved safety, as no severe adverse events were observed. Aclaris plans to further explore ATI-2138 in alopecia areata and other indications, which could expand its market potential. These factors, combined with the absence of significant safety risks typically associated with similar inhibitors, underpin Selvaraju’s confidence in the stock’s future performance, leading to the reiterated Buy rating and a 12-month price target of $16.
According to TipRanks, Selvaraju is a top 100 analyst with an average return of 26.3% and a 57.26% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Bioxcel Therapeutics, Axsome Therapeutics, and Cognition Therapeutics.